Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Burst-mode dual-comb spectroscopy.
Zhang Y, Weeks RRD, Lecaplain C, Harilal SS, Yeak J, Phillips MC, Jones RJ. Zhang Y, et al. Among authors: jones rj. Opt Lett. 2021 Feb 15;46(4):860-863. doi: 10.1364/OL.416668. Opt Lett. 2021. PMID: 33577532
Dual-comb spectroscopy of laser-induced plasmas.
Bergevin J, Wu TH, Yeak J, Brumfield BE, Harilal SS, Phillips MC, Jones RJ. Bergevin J, et al. Among authors: jones rj. Nat Commun. 2018 Mar 28;9(1):1273. doi: 10.1038/s41467-018-03703-0. Nat Commun. 2018. PMID: 29593235 Free PMC article.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, Flohr P, Miranda S, Bertan C, Ferreira A, Crespo M, Rodrigues DN, Gurel B, Nobes J, Crabb S, Malik Z, Ralph C, McGovern U, Hoskin P, Jones RJ, Birtle A, Gale J, Sankey P, Jain S, McLaren D, Chadwick E, Espinasse A, Hall E, de Bono J. Rescigno P, et al. Among authors: jones rj. Eur J Cancer. 2024 May 8;205:114103. doi: 10.1016/j.ejca.2024.114103. Online ahead of print. Eur J Cancer. 2024. PMID: 38729054 Free article.
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
Sinanidis I, Hochman MJ, Tsai HL, Randall MP, Bonilla B, Varadhan R, Ambinder AJ, Jones RJ, DeZern AE, Karantanos T. Sinanidis I, et al. Among authors: jones rj. Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299-y. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38714755 No abstract available.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. Among authors: jones rj. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Clinical Trial.
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Fizazi K, et al. Among authors: jones rj. Nat Med. 2024 Jan 31. doi: 10.1038/s41591-024-02835-9. Online ahead of print. Nat Med. 2024. PMID: 38297094 No abstract available.
744 results